IMWG immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Despite advances in drug therapies that have improved survival rates, multiple myeloma remains an incurable condition. Recent regulatory approvals for immunotherapies, including chimeric antigen receptor (CAR) T-cell therapy and T-cell-redirecting bispecific antibodies, have demonstrated remarkable efficacy. However, these novel treatments come with distinct mechanisms of action and unique toxicities, highlighting the need for guidance in patient management.
This document presents expert consensus clinical practice guidelines for the use of bispecific antibodies in treating myeloma.
Use Case
Type
Source
Content Collection
You might also like
BSH/UKMS good practice paper on Diagnosis and management of smouldering myeloma
Explore the latest guidelines for Smouldering Myeloma care in the British Society for Haematology Good Practice Paper.
BSH GuidelineNICE guidelines on Spinal metastases and metastatic spinal cord compression [NG234]
This NICE guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC).
NICE GuidelineIMWG recommendations on the management of multiple myeloma-related renal impairment
The IMWG outline updates to clinical practice guidance for the management of multiple myeloma-related renal impairment.
IMWG GuidelineIMWG consensus guidelines and recommendations for infection prevention in myeloma
Infection poses a significant risk to patients with multiple myeloma, contributing to high rates of morbidity and mortality. This consensus statement from the International Myeloma Society outlines essential guidelines for infection prevention
IMWG GuidelineBSH/UKMS guidelines on the Diagnosis, investigation, and initial treatment of myeloma
These new guidelines, produced by the British Society for Haematology (BSH) and the UK Myeloma Society (UKMS), provide healthcare professionals with guidance on the anti-myeloma management of patients with newly diagnosed myeloma.
IMWG recommendations for the treatment of multiple myeloma-related bone disease
This guideline, authored by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the current evidence and offers management recommendations for myeloma-related bone disease.
IMWG GuidelineNICE guideline on Acute kidney injury: prevention, detection and management [NG148]
This NICE guideline provides recommendations for non-specialists for the identification and referral guidance for children and adults who present with symptoms or risk factors of acute kidney injury.
NICE GuidelineIMWG consensus recommendations on imaging in monoclonal plasma cell disorders
The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
IMWG GuidelineMY-RADS guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma
As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.
Other GuidelineNICE guidelines on Venous thromboembolism in over 16s, reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism [NG89]
This NICE guidelines outlines how healthcare professionals can manage patients who may be at higher risk of developing VTE in hospital.
NICE Guideline
